Author: Wojciech Maruszczyk (Poland)
Co-authors: Agata Światowska, Dorota Śpiewak, Katarzyna Gontarz, Mariola Dorecka, Dorota Wyględowska-Promieńska, Ewa Mrukwa-Kominek
Purpose
Uveitic macular edema (UME) is a significant cause of visual impairment in all uveitis types. More than 30% of patients with uveitis can develop serious sight-threatening vision loss due to UME. Chronic intraocular inflammation leads to increase production of inflammatory cytokines that induces VEGF production in ocular tissues. It in turn disrupts blood retinal-barrier and increases vascular permeability leading to subsequent ME. It is found that aqueous VEGF concentration is significantly higher in patients with uveitic CME than those without CME. It may suggests a possible role of anti VEGF agents in the treatment of uveitic CME. Currently literature reports show VEGF inhibitors as a second-line treatment regiment, because they do not control inflammation. The aim of the study is to present a clinical case of using aflibercept in the treatment of central macular edema associated with uveitis.
Setting/Venue
Department of Ophthalmology, Prof. K. Gibiński University Clinical Centre, School of Medicine in Katowice, Medical University of Silesia in Katowice, Poland.
Methods
A 37-year-old man was referred to the Department of Ophthalmology, School of Medicine in Katowice, Medical University of Silesia in Katowice, Poland due to macular edema of the right eye, a year after viral retinitis of this eye (ARN), for further treatment. Ophthalmological diagnostics was performed: visual acuities, refractometry, tonometry, examination of the anterior and posterior segment of the eye in the slit lamp, fluorescein angiography (FA), color fundus photography, Optical Coherence Tomography (OCT) through the macula and a panel of laboratory were performed. The following treatments were applied: local NSAID as well as a systemic antyinflammatory therapy, with regression of macular edema and visual acuity improvement. Because of the primary infectious etiology of the inflammation and orthopedic contraindications to the continuation of the steroidotherapy treatment, intravitreal injections of aflibercept in individualized scheme, were applied.
Results
Before the treatment FA confirmed increased permeability in the posterior pole of the right eye fundus, with characteristic to macular edema “petaloid” leakage pattern. OCT through the macula revealed cystoid macular edema. After the anty-VEGF intravitreal treatment, improvement of the clinical condition in the right eye was achieved, i.e.: regression of the macular edema (from 601 µm to 303 µm), improvement of visual acuity (from 0.2 to 0.6). Results of the treatment were temporary and patient needed reinjections.
Conlusions
Intravitreal anti-VEGF therapy has a beneficial effect on the regression of the macular edema in the eyes with UME, however, its effect is temporary and reinjections are required during treatment. In individual cases, where the use of steroids is associated with an increased risk of side effects (cataract formation, intraoccular pressure elevation, reactivation of infectious causes of inflammation, steroid systemic complications), the use of anti-VEGF drugs as a first-line treatment may be considered. However, special care should be taken, as in the case of UME it is an “off label” treatment and may involve reactivation of the inflammatory process of the uveitis. Also, the strength of this therapy may not be sufficient and may require association with other medications.
Financial Disclosure
no financial interests to be reported
Comments
-